Sihuan Pharmaceutical's strategic investment in Switzerland's Suisselle to accelerate global aesthetic business expansion

On October 13, Sihuan Pharmaceutical Holdings Group Ltd. (0460.HK) announced that the Group completed an equity investment in Swiss aesthetic company Suisselle SA ("Suisselle") in September 2025, with both parties having formally executed the investment subscription agreement. This collaboration will enhance the strategic relationship between the Group and Suisselle, jointly expanding into the global aesthetic market.

Sihuan Pharmaceutical had previously secured the exclusive distribution rights for CELLBOOSTER® hydro-booster injections in China as early as 2022. This equity investment will further solidify the long-term collaborative partnership between both parties. Through this investment, Sihuan Pharmaceutical will permanently secure exclusive distribution rights for CELLBOOSTER® hydro-booster products and deeply engage in its operations and development.

Furthermore, following Sihuan Pharmaceutical's investment in Suisselle, the two parties will collaborate to leverage Suisselle's established European platform to accelerate the promotion and sales of Sihuan's self-developed aesthetic products in European and other overseas markets. Simultaneously, Sihuan will continue introducing innovative products from Suisselle and other European sources to diversify its aesthetic product portfolio in China, aiming to build an international aesthetic ecosystem that integrates R&D, manufacturing, and sales.